


HistoIndex secures S\$9 Million investment to drive next phase of expansion in digital pathology in Singapore

02 May 2025 | News | By Hithaishi C Bhaskar

Accelerating the adoption of advanced digital pathology solutions poised to transform MASH diagnosis and treatments



HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S\$9 million investment round to support its next phase of expansion.

Daniel Kwan, Global Head of the Mezzanine Capital Unit at OCBC, said: “HistoIndex’s groundbreaking technology has revolutionized liver disease diagnostics through cutting-edge AI innovations, and has the potential to enhance global healthcare by enabling precise and personalized patient care. We are proud to support this homegrown MedTech company with its growth plans and international ambitions.”

With the increasing demand for routine clinical testing of Metabolic Dysfunction-Associated Steatohepatitis (MASH), particularly in liver biopsy assessment, this investment is focused on 1) expanding HistoIndex-partnered laboratories and operations within the US; and 2) developing next-generation AI-powered SHG digital pathology tests for MASH patients.

In line with this mission, HistoIndex has recently launched its very first Laboratory Developed Test (LDT), FibroSIGHT™ – now available for order in the US. FibroSIGHT™ is designed to empower clinicians with accurate and consistent liver fibrosis assessment¹. The first in a pipeline of new product launches reaffirms HistoIndex's commitment to revolutionizing personalized treatment for MASH. By integrating research in pivotal clinical trials with clinical practice, the company is advancing precision medicine with the aim of improving patient outcomes worldwide.

"This investment plays an enabling role in positioning the company for strategic expansion within the US, while accelerating the adoption of advanced digital pathology solutions poised to transform MASH diagnosis and treatments." said Dr. Gideon Ho, Chief Executive Officer of HistoIndex.

OCBC, the longest established bank in Singapore and the second largest financial services group in Southeast Asia by assets, investing for the first time in a medical technology/healthcare company, leads the round with continued support from two existing shareholders – ZIG Ventures and SEEDS Capital, an investment arm of SG Growth Capital.